San Francisco’s UCSF is stepping into the national spotlight as one of several university medical centers testing whether a single dose of a lab-designed form of LSD can meaningfully calm chronic anxiety. In this Phase 3 clinical trial, volunteers receive one supervised morning dose in a clinic that is set up to feel more relaxing than clinical, then spend the day under observation. Researchers will follow participants for months to see how long any relief lasts, with the big question being whether a one-time treatment can deliver durable help for people whose generalized anxiety disorder has not responded to standard medications and talk therapy.
The study centers on MM120, an orally disintegrating tablet created by New York-based MindMed. The company describes its Voyage Phase 3 trial as a randomized, placebo-controlled study that will enroll about 200 adults across the United States, according to a press release from MindMed. The public trial record lists a 12-week double-blind period followed by a 40-week open-label extension on ClinicalTrials.gov. At UCSF, the Neuroscape lab is one of the active recruiting sites and invites interested adults to email a study contact for pre-screening, according to Neuroscape.
Early Data Hint at Long-Lasting Relief From One Dose
An earlier phase 2b, placebo-controlled study published in JAMA suggested that MM120 might pack a long punch. In that trial, a single 100-microgram dose led to rapid, clinically meaningful drops in anxiety scores that held up through 12 weeks. Roughly two-thirds of patients in the top-dose arm met response criteria, and nearly half reached remission. Most side effects, including visual or perceptual changes, nausea and headache, were reported as short-lived and largely limited to the dosing day.
Inside UCSF’s “Spa-Aesthetic” Dosing Room
At UCSF, the setting is deliberately designed to dial down the clinical vibe. Neurologist Jennifer Mitchell, who is leading the study on campus, told the San Francisco Chronicle that dosing days unfold in a calm, “spa-aesthetic” environment. Think dimmed lights, soft music, and a facilitator who stays with participants throughout the experience. Everyone is dosed in the morning and then spends a set number of hours in a living-room-style space, whether they received MM120 or placebo.
Who Can Enroll and What the Trial Measures
The Voyage study is currently recruiting adults ages 18 to 74 who have moderate-to-severe generalized anxiety disorder and meet a minimum entry score on the Hamilton Anxiety Rating Scale, according to the trial registry. Participants are typically required to stop medications that affect mood and to use effective birth control while in the study. The registry lists the primary outcome as the change in HAM-A score at week 12, and notes that eligible participants whose symptoms persist may receive open-label MM120 during the 40-week extension phase, per ClinicalTrials.gov
Why Psychedelic Researchers Are Keeping a Close Eye
MM120 is part of a broader wave of clinical psychedelic research aimed at conditions that have stubbornly resisted existing treatments. The field has attracted serious scientific interest along with plenty of hype. Josh Woolley, who directs UCSF’s translational psychedelic research program, cautioned that a “gold-rush” mentality is taking shape even as regulators and clinicians push for larger, longer studies to really nail down safety and durability, according to the San Francisco Chronicle.
